The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
 
Viktor Grünwald
Honoraria - Bayer; Bristol-Myers Squibb; Cerulean Pharma; Eisai; Exelixis; Ipsen; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; PharmaMar; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Cerulean Pharma; Ipsen; Lilly; MSD Oncology; Novartis; Pfizer
Speakers' Bureau - Novartis; Pfizer
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; MSD Oncology; Novartis; Pfizer
 
Thomas E. Hutson
Employment - Texas Oncology
Honoraria - Bayer/Onyx; Dendreon; GlaxoSmithKline; Johnson & Johnson; Medivation; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer/Onyx; GlaxoSmithKline; GlaxoSmithKline; Novartis; Pfizer
Speakers' Bureau - Bayer/Onyx; Dendreon; GlaxoSmithKline; Johnson & Johnson; Medivation; Pfizer
Research Funding - GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Medivation (Inst); Pfizer (Inst)
 
Camillo Porta
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Eisai; EUSA Pharma; EUSA Pharma; Ipsen; Ipsen; Janssen; Janssen; Novartis; Novartis; Peleton; Peleton; Pfizer; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Eisai; Ipsen; Ipsen; Novartis; Novartis; Pfizer; Pfizer
Research Funding - Pfizer (Inst)
 
Thomas Powles
Honoraria - Bristol-Myers Squibb; MERCK; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
Other Relationship - Bristol-Myers Squibb; Ipsen
 
Masatoshi Eto
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Speakers' Bureau - Astellas Oncology; Bayer Health; Bristol-Myers Squibb; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Sanofi; Shionogi; Takeda
Research Funding - Astellas Oncology; Lilly; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Takeda
 
Corina E. Dutcus
Employment - Eisai
Leadership - Eisai
 
Mahadi Ali Baig
Employment - Eisai
 
Lea Dutta
Employment - Eisai
 
Di Li
Employment - Eisai
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - alligent; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Peloton Therapeutics; Pfizer; Prometheus; Roche/Genentech
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - advisory boards/consultancy